Pharmaceutical Patient Assistance Programs Expand throughout the World

Over the last few months, several pharmaceutical companies have announced new donations and programs regarding vaccines, as well as increasing access to medicines for important diseases. Below is a summary of some of these activities and we will try to update the story as we come across other announcements. GlaxoSmithKline In late July, GlaxoSmithKline (GSK) announced that it would increase its commitment to the GAVI Alliance to provide vaccines to developing countries, helping to protect millions more children against infectious diseases. Under this new agreement, GSK will provide an additional 240 million doses of Synflorix™ to developing countries over the next ten years, helping protect up to 80 million more children from pneumococcal diseases such as meningitis and pneumonia. This builds on the 480 million doses of the vaccine that GSK has already committed to GAVI through the Advance Market Commitment (AMC) framework, which is designed to bring heavily discounted vaccines to children living in the world's poorest countries. GSK provides GAVI with a broad portfolio of vaccines including: Synflorix which protects against pneumococcal disease; Rotarix™ vaccination for rotavirus, a common cause of diarrhoea; Cervarix® which helps protect girls against cervical cancer caused by human papilloma virus; and a combined vaccination for diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b. With this new vaccine supply agreement ex...
Source: Policy and Medicine - Category: Health Medicine and Bioethics Commentators Authors: Source Type: blogs